Kornimate/medical-research-clean huggingface dataset:
cognitive function and eeg brain network remodeling among users of hearing aids with arhl

Conditions: Age-related Hearing Loss; Age-related Cognitive Decline; Depression; Sleep Disturbance

Summary: this study intends to retrospectively collect and analyze the case data of patients with age-related hearing loss who were admitted to the otolaryngology department of sun yat-sen memorial hospital from january 2020 to june 2024. participants were divided into an aided group and a control group based on whether they had regularly used hearing aids in the past six months. audiological, cognitive, emotional, and sleep assessments, as well as resting state electroencephalogram (eeg) features, are supposed to be compared between the two groups.

this study intends to retrospectively collect and analyze the case data of patients with age-related hearing loss who were admitted to the otolaryngology department of sun yat-sen memorial hospital from january 2020 to june 2024. participants were divided into an aided group and a control group based on whether they had regularly used hearing aids in the past six months. the audiological assessment comprises pure tone audiometry, speech recognition audiometry, and sound field audiometry. the cognitive assessment includes the mandarin version of the montreal cognitive assessment (moca) and the mini-mental state examination (mmse). the emotional assessment consists of the 24-item hamilton depression scale (hamd) and the 15-item geriatric depression scale (gds). sleep assessment is conducted using the pittsburgh sleep quality index (psqi).

Eligibility criteria:
inclusion criteria: * diagnosed with arhl * aged between 50 and 90 * complete measuring data; including pure tone audiometry, speech audiometry, cognitive screening scales and resting-state electroencephalography * right-handed * regular daily use of hearing aid(s) for six-month period prior to the test date, or no hearing aid experience exclusion criteria: * outer/middle ear abnormalities or any other central nervous system disorders

Keywords: age-related hearing loss cognition electroencephalogram
perioperative evaluation of mmp-9-timp-1 system in vascular surgery regarding ischemic-reperfusion injury

Conditions: Ischemia Reperfusion Injury

Summary: the mmp-9-timp-1 system has been implicated in many physiological and pathophysiological conditions including vascular surgery related ischemic-reperfusion injury. our key aims were to establish the early perioperative time courses of the aforementioned system in aorto-bifemoral bypass and aorta stentgraft implantation procedures and to find correlation between the mmp-9-timp-1 system and the cross-clamp time. patients were prospectively enrolled after ethical committee approval. blood samples were taken at four different time points (t1-4): t1: right before surgery, t2: 60 min after the cross-clamp release, t3: first postoperative morning, t4: third postoperative morning. plasma was isolated from heparin anticoagulated blood samples by low speed centrifugation at 4 °c, and stored at -80 °c until analyzed in a single batch at the end of the study. mmp- 9 and timp-1 were determined by the quantitative sandwich enzyme-linked immunosorbent assay (elisa) techniques according to the manufacturer instructions (r\&d systems inc., minneapolis, minnesota, usa). in comparison with standard curves, the concentrations of mmp-9 and timp-1 in plasma were determined spectrophotometrically (multiskan ascent microplate photometer, type: 354, thermo electron corporation, waltham, massachusetts, usa) by reading the absorbance at 450 nm. plasma concentrations of mmp-9 and timp-1 were expressed as ng/ml.


Eligibility criteria:
inclusion criteria: * scheduled for elective procedure (aorto-bifemoral bypass or aorta stentgraft implantation) by vascular surgeons. * over age 18 * agree to participate exclusion criteria: * under age 18 * refuse to participate * diagnosed malignant disease * chronic steroid usage * being on cytostatic therapy

Keywords: matrix metalloproteinase tissue inhibitor of matrix metalloproteinase vascular surgery aorta stent implantation aorto-bifemoral bypass surgery
exercise as a modulator of immune risk factors for ischemic heart disease

Conditions: Heart Diseases

Summary: a before and after study involving 43 adult subjects at risk of having ischemic heart disease. subjects underwent 6 months of supervised moderate intensity aerobic and resistive exercise training. blood samples were obtained at entry and at 6 months for measurement of complement (c3), crp, blood lipid levels, lymphocyte phenotypes, and for the isolation, culture, and measurement of the spontaneous and phytohemagglutinin-induced secretion of proatherogenic and antiatherogenic cytokines by their peripheral blood mononuclear cells (pbmc).

a before and after study involving 43 adult subjects at risk of having ischemic heart disease. subjects underwent 6 months of supervised moderate intensity aerobic and resistive exercise training. blood samples were obtained at entry and at 6 months for measurement of complement (c3), crp, blood lipid levels, lymphocyte phenotypes, and for the isolation, culture, and measurement of the spontaneous and phytohemagglutinin-induced secretion of proatherogenic and antiatherogenic cytokines by their peripheral blood mononuclear cells (pbmc

Eligibility criteria:
inclusion criteria: * normal ekg * normal stress test exclusion criteria: * abnormal ekg * abnormal stress test * presence of a chronic inflammatory disease * presence of malignancy * immunosuppressive therapy

Keywords: exercise hyperlipidemia tnf-alpha atherogenesis ldl-cholesterol oxidized ldl-c
safety and efficacy of celecoxib versus sodium diclofenac in the treatment of acute low back pain

Conditions: Low Back Pain

Summary: to evaluate the safety and efficacy of celecoxib versus sodium diclofenac in subjects with acute low back pain


Eligibility criteria:
inclusion criteria: * aged between 18 and 65 years * acute low back pain that falls into 1st or 2nd class of 'quebec task force' classification of moderate to severe intensity (\>50 mm in the vas) * acute low back pain onset \ 6 weeks after the last acute low back pain episode exclusion criteria: * scoliosis or known history of inflammatory arthritis, chronic pain, metastasis, paget's disease, or any other disease that cause pain * low back pain from major trauma or visceral disorder * esophageal ulcers, gastric or duodenal ulcers or bleeding within 30 days prior to being administered study drug
double-blind, parallel, randomised study to investigate the effect of oral probiotics in infants with atopic dermatitis

Conditions: Atopic Dermatitis; Atopic Eczema; Infantile Eczema

Summary: to study the effect of supplementation of a hydrolyzed formula with probiotic bacteria on clinical and immunological parameters in infants with ad with and without cma and to compare effectiveness of different strains of probiotics.

* to determine the effect of supplementation of a hydrolyzed formula with probiotic bacteria on clinical and immunological parameters in infants with ad with and without cma * to determine the effect of supplementation of a hydrolyzed formula with probiotic bacteria on clinical and immunological reactivity to cow' milk challenge in infants with ad with cma * to compare the effectiveness of different strains of probiotic bacteria in improving clinical and immunological outcome in these infants

Eligibility criteria:
inclusion criteria: * term infants fulfilling the hanifin (1989) criteria for atopic dermatitis * suggestive of cma (one additional symptom) * scorad index (total) \>20 at study entry * below 5 months of age * formula, not breast fed * written informed consent from the parents exclusion criteria: * • previous or current use of anti-histamines, oral corticosteroids, probiotics * use of systemic antibiotic or anti-mycotic drugs in the previous 4 weeks * congenital intestinal abnormality (eg. hirschsprung's disease, intestinal atresia) * other gi disease with intestinal inflammation and/or increased intestinal permeability * skin disorder, not atopic dermatitis * participation in another clinical study

Keywords: atopic dermatitis scorad probiotics cytokines infant
reflux esophagitis phase iii study (initial treatment)

Conditions: Reflux Esophagitis

Summary: this study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of reflux esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of reflux esophagitis at week 8 according to the los angeles classification .


Eligibility criteria:
inclusion criteria: * endoscopically verified reflux esophagitis classified into los angeles classification grade a, b, c or d within 1 week before randomisation exclusion criteria: * gastric or duodenal ulcer verified by egd within 12 weeks before randomisation. * use of any ppi from 14 days before egd performed at the screening visit to the day of randomisation.

Keywords: reflux esophagitis
aerobic walking exercise for non-ambulatory stroke survivors

Conditions: Stroke

Summary: by doing this study, researchers hope to learn the effects of aerobic exercise on heart, lung, and bone health in people who cannot walk after a stroke.


Eligibility criteria:
inclusion criteria: * independent ambulation before stroke * be able to understand and follow verbal commands in english * have physicians' approval for exercise, and be in stable medical condition * participant's first stroke * unable to walk independently according to functional ambulation category (fac) (\<2) after in-patient rehabilitation treatment * between 6 weeks to 5 years after stroke onset exclusion criteria: * current cardiovascular abnormalities other than stroke such as ischemic cardiovascular event or coronary artery bypass surgery less than 3 months ago * musculoskeletal disorder which prevents subjects from participating in the exercise * resting blood pressure more than 200/110 mm hg * current or previous pulmonary diseases in the past two years * osteoporosis and restricted passive movement in the major joints of the lower limbs * subjects will be excluded if they are unable to speak or understand english and/or unable to travel to the university of kansas medical center (kumc) neuromuscular research laboratory
effects of a videogame-based program on women with lymphedema secondary to breast cancer

Conditions: Lymphedema; Breastcancer

Summary: aims: to demonstrate the effect of a program based on video games as a means to improve abilities and basic skills affected by lymphedema, and its impact on quality of life. design: longitudinal, pre-experimental, with pre / post-test and evaluation, assessor blinded study. method: data on shoulder pain and disability, health-related quality of life, strength and articulate activated by the oss (oxford shoulder score), spadi (shoulder pain and disability index), fact-b + 4 (functional assesment of cancer therapy questionnaire for breast cancer), respectively goniometry and dynamometry amplitude scales will be collected. the intervention will be performed with the wii ™ console and the wii balance boardtm, during 5 individual weekly sessions of 30 minutes.


Eligibility criteria:
inclusion criteria: * be over 18 years * have a diagnosis of lymphedema, secondary to breast cancer exclusion criteria: * stage 0 or subclinical lymphedema * present other shoulder pathology apart from lymphedema

Keywords: video games
tolvaptan add-on therapy to overcome loop diuretic resistance in acute heart failure with renal dysfunction

Conditions: Acute Heart Failure

Summary: renal dysfunction, which comprises 10%-40% of acute heart failure patients (ahf), plays an important role in diuretic resistance mechanism. dr-ahf was designed to demonstrate the effectiveness of early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in acute heart failure patients with renal dysfunction and clinical evidence of loop diuretic resistance.

this is a single-center, open-label, randomized controlled trial, which will enroll 128 patients hospitalized due to ahf. these patients with wet-warm phenotype whose estimated glomerular filtration rates at admission are above 15 and below 60 ml/min/1.73 m2, and cumulative urine output \<300 ml in 2 hours after the first dose of intravenous furosemide will be randomly assigned 1:1 to receive a standard care with uptitrating intravenous furosemide alone or a combination therapy with tolvaptan 15mg once daily for 2 days. the standard furosemide treatment will follow the modified 2019 position statement from the esc heart failure association. the primary endpoint is the cumulative urine output at 48 hour. key secondary endpoints include the improvement of fractional excretion of sodium at 6 hour, the total dose of furosemide, the changes in the body weights, the net fluid loss, the lessening of diastolic dysfunction parameters on echocardiography, and the incidence of clinically relevant worsening renal function at 48 hour.

Eligibility criteria:
inclusion criteria: * admitted to hospital with a primary diagnosis of acute heart failure with wet-warm phenotype * cumulative urine volume output \< 300ml within 2 hours after the first dose of intravenous furosemide * egfr at admission 15-60ml/min/1.73m2 exclusion criteria: * acute coronary syndrome * anuria * sepsis * consciousness impairment * pregnant or breastfeeding women * severe valvular heart diseases (severe valvular stenosis or regurgitation) * admission sodium level \> 140 meq/l * serum total bilirubin \> 3 mg/dl * serum potassium \> 5.5 mmol/l * allergy or contraindication for tolvaptan * emergency indication for hemodialysis * cardiogenic shock or mechanical circulation support

Keywords: acute heart failure worsening renal function loop diuretic resistance vasopressin-2 receptor antagonist
synergistic effect of elemene plus tkis compared with tkis in egfr-mutated advanced nsclc：retrospective study

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a nationwide, multicenter and retrospective cohort study. the purpose of this study is to evaluate the synergistic effect and safety of elemene plus tkis in egfr-mutated advanced non-small cell lung cancer.

about 9.2%-45.8% of chinese patients with non-small cell lung cancer were positive for egfr gene mutation. gefitinib, erlotinib, icotinib, afatinib showed efficacy superior to that of chemotherapy in the treatment of egfr mutation positive advanced nsclc, and lower rates of serious adverse events. however, after a median of 8 to 13 months of disease control, patients ultimately progress due to acquired resistance of egfr-tkis. elemene, a chemotherapeutic isolated from the chinese medicinal herb rhizoma zedoariae, has been shown to have a comprehensive anti-tumor effect and the potential effect on reversing drug resistance. the study is a real-world study and the case records of patients with advanced non-small cell lung cancer who visited the research centers from january 2014 to december 2017 and met the inclusion criteria will be collected. medical data including patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, and so on will be extracted to evaluate the synergistic effect and safety of elemene plus tkis in egfr-mutated advanced non-small cell lung cancer.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed advanced non-small cell lung cancer(stage iiib\~iv). 2. patients with egfr mutation. 3. received egfr-tkis at least once. 4. received elemene injectable emulsion and/or elemene oral emulsion at least once ( only for elemene plus tkis group). 5. completeness of important outcome measures and medical records related to the study. exclusion criteria: 1. accompanied by other active tumors. 2. the researchers did not consider it appropriate to participate in this study for other reasons.

Keywords: elemene, tki, egfr, real world study
bilateral knee osteoarthritis: intra-articular injection of filtered autologous adipose tissue versus placebo

Conditions: Bilateral Knee Osteoarthritis; Autologous Adipose Tissue

Summary: the purpose of the study is to assess the radiological and clinical outcomes comparing two different treatments (filtered autologous adipose tissue versus placebo) in patients affecting bilateral knee osteoarthritis. after be randomized, every patient will be treated in both legs, one leg with adipose tissue and the other one with placebo.

all patients who meet the inclusion criteria and giving written informed consent will be randomized. every patient will be treated with a single injection of filtered autologous adipose tissue in one knee and single injection of placebo in the other, based on the randomization. after the treatment patients will be followed up to 24 months.

Eligibility criteria:
inclusion criteria: 1. bilateral degenerative chondropathy of the knees showing at least a grade 2-3 kellgren-lawrence classification (absence of severe osteoarthritis) 2. an overall pain subscale score of the western ontario and mcmaster universities osteoarthritis index between a value of 9 and 19. 3. failure, intended as the persistence of symptomatology, after at least one conservative treatment cycle (pharmacological, physiotherapeutic or infiltrative treatment); 4. ability and informed consent of patients to actively participate in the rehabilitation protocol and clinical and radiological follow-up; exclusion criteria: 1. patients incapable of understanding and wanting; 2. diagnosis of leukaemia, known presence of metastatic malignant cells, ongoing or planned chemotherapy; 3. diagnosis of rheumatoid arthritis, reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis or arthritis resulting from another inflammatory disease; infection with human immunodeficiency virus (hiv), viral hepatitis; chondrocalcinosis; 4. patients with uncontrolled diabetes mellitus; 5. patients with uncontrolled thyroid metabolic disorders; 6. patients who abuse alcoholic beverages, drugs or medicines; 7. patients with misalignment of the lower limbs above 10 degrees; 8. body mass index \> 40; 9. pregnant or lactating state or intention to become pregnant during the period of participation in the study. 10. patients with a history of trauma or intra-articular infiltration of therapeutic substances in the 6 months prior to screening. 11. patients who have had knee surgery in the 12 months prior to screening. 12. patients with insufficient abdominal adipose tissue, assessed by the investigator

Keywords: arthrosis osteoarthrosis degenerative joint disease knee degenerative joint disease. bilateral fat tissue
a study for participants with pancreatic cancer

Conditions: Pancreatic Neoplasms

Summary: the purpose of the phase 1 portion of this study was to determine the dose of ly2603618 that can be safely administered 24 hours after gemcitabine treatment. this dose was then used for the phase 2 portion of the study. the phase 2 portion of the study evaluated whether ly2603618, when administered 24 hours after gemcitabine therapy, was an effective treatment for participants with pancreatic cancer.

phase 1 included a dose escalation of ly2603618 doses from 70 milligrams/meter squared (mg/m\^2) to 250 mg/m\^2 divided into 5 cohorts. each participant was assigned to a single cohort with no intra-participant dose escalation. phase 1 also included an expansion cohort where participants received a flat dose of 200 or 230 mg ly2603618. participants received gemcitabine on days 1, 8, and 15, followed by ly2603618 on days 2, 9, and 16 of each 28-day cycle. the purpose of the phase 1 portion was to determine the maximum tolerated ly2603618 dose to be carried into the phase 2 portion of the study.

Eligibility criteria:
inclusion criteria: * diagnosed with cancer that is metastatic and/or advanced during phase 1 * diagnosed with pancreatic cancer that is metastatic and not amenable to surgery * must be at least 18 years of age * adequate hematological, liver, and renal functions * eastern cooperative oncology group (ecog) status of 0 to 2 exclusion criteria: * known hypersensitivity to gemcitabine * pregnant or lactating females or refusal to use medically approved contraceptive precautions * had prior treatment with radiotherapy involving more than 25% of marrow producing area * have received treatment in the last 30 days with a drug which has not received regulatory approval for any indication at the time of study entry

Keywords: pancreas metastatic cancer advanced cancer pancreatic cancer
the improvement of black raspberry in obese and mild az patients infected with h. pylori

Conditions: Alzheimer Disease; H Pylori Infection

Summary: the current study was designed to check the impact of black raspberry (br) on obese and mild alzheimers (az) patients infected with helicobacter pylori (h pylori). through checking various parameters including anthropometric, antioxidants, and cdr.

the current study was designed to check the impact of black raspberry (br) on obese and mild alzheimers (az) patients infected with helicobacter pylori (h pylori). preclinical studies (in vitro model) were conducted using 3t3-l1 adipocyte cells to check the anti-adhesion activity of br. for the clinical trial, a total of 21 obese mild az patients were recruited and separated into 2 groups: experimental (br group) and placebo group. experimental group and placebo group subjects were requested to take either 50 g of br or 50 g of dextrin respectively for 4 weeks.

Eligibility criteria:
inclusion criteria: * bmi ≧ 27, waist circumference: men ≧ 90cm, women ≧ 80cm, * body fat: male ≧ 25%, female ≧ 30%, * ubt 13c test value\> 10‰ (h. pylori (+)), * cdr (clinical dementia rating) = 0.5 exclusion criteria: * bmi\< 27 * severe chronic diseases (liver disease, cardiovascular disease, kidney disease) * alcohol abuse * smoking habit * taking berry-related supplementation or any known allergies related to berries. * subjects with prior history of h. pylori infection were treated with triple therapy.

Keywords: black raspberry alzheimer's patients h pylori inflammatory cytokines antioxidant
comparison of the severity of coronary atherosclerosis with tissue compliance in patients within first degree relatives

Conditions: Coronary Artery Disease With Myocardial Infarction

Summary: this study research the similarity of coronary artery lesions according to hla tissue compatibility in fisrt degree relatives of the patients who just admitted clinic as acute coronary syndrome and underwent angiyography before .

coronary artery disease (cad), which is mainly caused by atherosclerosis, is the most prevalent illness and the leading cause of death worldwide. increasing evidence suggests that inflammation plays a primordial role in atherogenesis and is closely associated with the major histocompatibility complex (mhc) (human leukocyte antigen \[hla\] in humans) molecules. hla genes are located in 6p21.3, the proteins encoded by these hla genes have a major role to play in antigen presentation and inflammatory pathways. hla involvement in inflammation is mainly associated with the hla-dependent activation of t cells. studies reported that the susceptibility to cad is related with the polymorphisms in hla-drb1. the above evidence indicates that the polymorphisms in hla class ii are associated with the risk of cad . this study research investigate three objects , firstly what is the similarity of the coronary artery lesions according to the compatability of hla alleles between the first degree relatives who went angiography before , secondly is there any relation between hla subtype allels and the coronary artery (rca ?lad ? ,cx? and can such a relation be responsible from the lesions in this artery ,finally is there any relation between hla subtypes and turkish race coronary artery disease

Eligibility criteria:
inclusion criteria: * male or female with age between 18-70 * hospital admission due to acute coronary syndrome with first degree relative history who had coronary angiyography before exclusion criteria: * first degree relative without any angiyography history before for patients who admitted as acute coronary syndrome